Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

Patient Relevant Outcomes Improvement Program in High Risk HR-positive Breast Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07531693

Acronym

PROSPER

Enrollment

200

Registered

2026-04-15

Start date

2026-02-19

Completion date

2027-03-01

Last updated

2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HR+/HER2- Early Breast Cancer

Brief summary

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Femal patients age 18 or older at time of informed consent * Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis) * Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC) * Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025

Exclusion criteria

* Locally advanced or metastatic breast cancer * Male patients * Patients with contraindication(s) for abemaciclib therapy according to SmPC

Design outcomes

Primary

Measure	Time frame	Description
Abemaciclib persistence rate	6 months after therapy start	Abemaciclib persistence rate (defined as ongoing abemaciclib therapy)

Countries

Germany

Contacts

CONTACTSponsor's study office

studien@ifg-erlangen.de+49 15739466438

STUDY_CHAIRPeter A. Fasching, Prof. Dr. med.

Department of Obstetrics and Gynaecology, Uniklinikum Erlangen

Outcome results